Core Viewpoint - The company, Beijing University Pharmaceutical (000788.SZ), has received approval from the National Medical Products Administration for the drug registration certificate of Apremilast tablets in two specifications (10mg and 30mg) [1] Group 1: Product Details - Apremilast is a specific small molecule inhibitor of phosphodiesterase-4 (PDE4) that regulates intracellular inflammatory signaling pathways [1] - The drug effectively inhibits the release of pro-inflammatory factors and increases the generation of anti-inflammatory factors, thereby precisely controlling inflammatory responses [1] - Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, characterized by rapid onset, clear efficacy, and high safety [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Apremilast tablets in two specifications (10mg and 30mg) [1] Company Summary - Apremilast is a specific small molecule inhibitor of phosphodiesterase-4 (PDE4) that regulates intracellular inflammatory signaling pathways, effectively inhibiting the release of pro-inflammatory factors and increasing the production of anti-inflammatory factors [1] - The drug is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, characterized by rapid onset, clear efficacy, and high safety [1]